{"id":344223,"date":"2026-11-11T21:15:05","date_gmt":"2026-11-11T15:45:05","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/pharmaids-pharmaceuticals-q2-results-fy27-loss-2-crore\/"},"modified":"2026-11-11T21:15:05","modified_gmt":"2026-11-11T15:45:05","slug":"pharmaids-pharmaceuticals-q2-results-fy27-loss-2-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharmaids-pharmaceuticals-q2-results-fy27-loss-2-crore\/","title":{"rendered":"Pharmaids Pharmaceuticals Q2 Results FY27: Loss Narrows 43.96%, Revenue Rs 4.34 Cr, PAT Rs -1.81 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Pharmaids Pharmaceuticals Q2 Results FY27 were declared on 11 November 2026 on a consolidated basis. Revenue was Rs 4.34 Cr, down 49.59% YoY from Rs 8.61 Cr, while net profit was Rs -1.81 Cr against Rs -3.23 Cr a year ago, a net loss that improved by 43.96%. These quarterly results show a YoY decline in revenue alongside a smaller net loss, so YoY growth is mixed across the two lines.<\/p>\n<\/div>\n

Pharmaids Pharmaceuticals Ltd<\/a> (PHARMAID) Q2 Results FY27 announced on 11 November 2026, covering the company’s financial performance for the July to September quarter. The results date brought consolidated revenue of Rs 4.34 Cr and a PAT of Rs -1.81 Cr, and the Pharmaids Pharmaceuticals Q2 Results FY27 figures are presented on a consolidated basis, so every number in this article reflects the consolidated results of the group.<\/p>\n

The Pharmaids Pharmaceuticals Q2 Results release is covered here through a results analysis of the financial highlights, business drivers, outlook and risks, with the key figures from the BSE filing set out in the Financial Highlights table that follows. Univest tracks the same figures for readers who follow the stock.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n